| Project/Area Number |
23390328
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
TAKETOMI Akinobu 北海道大学, 医学(系)研究科(研究院), 教授 (70363364)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAEHARA Yoshihiko 九州大学, 大学院・医学研究科, 教授 (80165662)
SHIRABE Ken 九州大学, 大学院・医学研究科, 准教授 (70264025)
MATSUURA Yoshiharu 大阪大学, 微生物病研究所, 教授 (50157252)
FUKUHARA Takasuke 大阪大学, 微生物病研究所, 助教 (70598739)
YOSHIZUMI Tomoharu 九州大学, 大学院・医学研究科, 准教授 (80363373)
UCHIYAMA Hideaki 九州大学, 大学病院, 特任助教 (70380425)
|
|---|
| Project Period (FY) |
2011-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2013: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2011: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Keywords | 肝移植 / C型肝炎 / 遺伝子多型 / SVR / SNP / Ｃ型肝炎 / ＩＬ28Ｂ遺伝子多型 / ゲノム |
|---|
| Research Abstract |
A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus-positive recipients was performed in Japan. Of 514 recipients collected in the study, 361 patients underwent antiviral treatment after liver transplantation. VR rate was 64.1%, and SVR rate was 38.3%. The 5-yr and 10-yr cumulative patient survival with SVR (94.1% and 83.0%) were significantly superior than those without SVR (79.7% and 60.8%). Presence of the major allele (TT) in both the recipient and the donor corresponded to SVR of 58.2%. Presence of the minor allele (TG or GG) in either the recipient or the donor corresponded to SVR of 15.7%, 16.7% and 28.5%. Multivariate analysis revealed that genotype of IL28B polymorphisms in either the recipient or donor was an independent factor for achieving SVR. In conclusion, our study demonstrated that both donor and recipient IL28B genotype were strongly associated with graft survival and response to IFN/RBV therapy for LDLT recipients.
|
